









市场行情
/
股票
/
nasdaq-lgnd
/

Ligand Pharmaceuticals Inc

LGND

133.835USD

+1.115+0.84%

交易中（美东）报价延迟15分钟

2.58B总市值

亏损市盈率 TTM



Ligand Pharmaceuticals Inc

133.835

+1.115+0.84%

概览公司财务

Ligand Pharmaceuticals Incorporated 是一家生物制药公司，通过支持药物的临床开发来推动科学进步。该公司通过提供融资、授权其技术或两者兼而有之来实现这一目标。其 Captisol 平台技术是一种化学改性环糊精，其结构旨在优化药物的溶解度和稳定性。该技术已使多种美国食品药品管理局 (FDA) 批准的产品成为可能，包括吉利德的 Veklury、安进的 Kyprolis、百特国际的 Nexterone、Melinta Therapeutics 的 Baxdela 和 Sage Therapeutics 的 Zulresso。其技术还包括 HepDirect、LTP 和 BEPro 技术平台、SUREtechnology 平台（由 Selexis 拥有）和 Pelican Expression Technology。该公司已与安进、默克、辉瑞、Jazz、武田、吉利德科学和百特国际等多家制药公司建立了多个联盟、许可和其他业务关系。

公司简介

公司代码LGND

公司名称Ligand Pharmaceuticals Inc

上市日期Nov 18, 1992

CEOMr. Todd C. Davis

员工数量68

证券类型Ordinary Share

年结日Nov 18

公司地址555 Heritage Drive, Suite 200

城市JUPITER

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编33458

电话18585507500

网址https://www.ligand.com/

公司代码LGND

上市日期Nov 18, 1992

CEOMr. Todd C. Davis

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Jason M. Aryeh

Independent Director

137.16K

+0.89%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

45.30K

-2.02%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

+3.93%

Mr. Andrew Reardon

Chief Legal Officer

17.05K

-4.31%

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

10.12K

+2.26%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

+14.86%

Mr. Jason Haas

Independent Director

6.86K

+21.40%

Dr. Martine Zimmermann, Pharm.D.

Independent Director

4.29K

+31.26%

Mr. Todd C. Davis

Chief Executive Officer, Director

名称

名称/职务

职务

持股

持股变动

Mr. Jason M. Aryeh

Independent Director

137.16K

+0.89%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

45.30K

-2.02%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

+3.93%

Mr. Andrew Reardon

Chief Legal Officer

17.05K

-4.31%

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

10.12K

+2.26%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Captisol

13.46M

29.69%

Qarziba

5.44M

12.00%

Filspari

5.30M

11.69%

Kyprolis

4.72M

10.42%

Milestone

4.38M

9.67%

Other

12.02M

26.52%

暂无数据

业务

地区

业务USD

名称

营收

占比

Captisol

13.46M

29.69%

Qarziba

5.44M

12.00%

Filspari

5.30M

11.69%

Kyprolis

4.72M

10.42%

Milestone

4.38M

9.67%

Other

12.02M

26.52%

股东统计

更新时间: 5月16日周五

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.86%

The Vanguard Group, Inc.

10.63%

Janus Henderson Investors

5.33%

Macquarie Investment Management

4.70%

Dimensional Fund Advisors, L.P.

3.86%

Other

61.62%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.86%

The Vanguard Group, Inc.

10.63%

Janus Henderson Investors

5.33%

Macquarie Investment Management

4.70%

Dimensional Fund Advisors, L.P.

3.86%

Other

61.62%

股东类型

持股股东

占比

Investment Advisor

57.94%

Investment Advisor/Hedge Fund

37.89%

Individual Investor

2.39%

Research Firm

1.84%

Pension Fund

1.60%

Bank and Trust

0.41%

Sovereign Wealth Fund

0.28%

Hedge Fund

0.05%

Insurance Company

0.03%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

534

19.71M

102.14%

-793.05K

2025Q1

554

19.82M

102.82%

-711.89K

2024Q4

546

19.28M

100.16%

-1.51M

2024Q3

543

19.17M

104.83%

-583.22K

2024Q2

527

18.31M

101.74%

-865.78K

2024Q1

520

17.60M

99.35%

-393.03K

2023Q4

527

16.97M

97.29%

-861.76K

2023Q3

515

17.24M

99.38%

-910.17K

2023Q2

526

17.09M

98.94%

-1.02M

2023Q1

528

16.47M

96.50%

-1.33M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

2.67M

13.86%

-26.33K

-0.97%

Mar 31, 2025

The Vanguard Group, Inc.

2.05M

10.63%

-29.89K

-1.44%

Mar 31, 2025

Janus Henderson Investors

1.03M

5.33%

+12.53K

+1.23%

Mar 31, 2025

Macquarie Investment Management

906.23K

4.7%

+21.85K

+2.47%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

744.93K

3.86%

+21.91K

+3.03%

Mar 31, 2025

State Street Global Advisors (US)

727.13K

3.77%

-16.51K

-2.22%

Mar 31, 2025

Congress Asset Management Company, LLP

642.71K

3.33%

+21.23K

+3.42%

Mar 31, 2025

Stephens Investment Management Group, LLC

607.22K

3.15%

-5.56K

-0.91%

Mar 31, 2025

Chicago Capital, LLC

554.52K

2.87%

+2.93K

+0.53%

Mar 31, 2025

Geode Capital Management, L.L.C.

464.45K

2.41%

+26.01K

+5.93%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Invesco Pharmaceuticals ETF

3.03%

Virtus LifeSci Biotech Products ETF

1.91%

SPDR S&P Pharmaceuticals ETF

1.86%

Franklin Genomic Advancements ETF

1.68%

Invesco S&P SmallCap Health Care ETF

1.57%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.34%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.32%

iShares U.S. Pharmaceuticals ETF

1.1%

First Trust Multi-Manager Small Cap Opportunities ETF

0.71%

Simplify Health Care ETF

0.52%

Invesco Pharmaceuticals ETF

占比3.03%

Virtus LifeSci Biotech Products ETF

占比1.91%

SPDR S&P Pharmaceuticals ETF

占比1.86%

Franklin Genomic Advancements ETF

占比1.68%

Invesco S&P SmallCap Health Care ETF

占比1.57%

Pacer US Small Cap Cash Cows Growth Leaders ETF

占比1.34%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.32%

iShares U.S. Pharmaceuticals ETF

占比1.1%

First Trust Multi-Manager Small Cap Opportunities ETF

占比0.71%

Simplify Health Care ETF

占比0.52%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

KeyAI

